The treatment of Graves' disease in children and adolescents.
10.6065/apem.2014.19.3.122
- Author:
Hae Sang LEE
1
;
Jin Soon HWANG
Author Information
1. Department of Pediatrics, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea. pedhwang@ajou.ac.kr
- Publication Type:Review
- Keywords:
Hyperthyroidism;
Graves' disease;
Antithyroid agents
- MeSH:
Adolescent*;
Antithyroid Agents;
Child*;
Drug Therapy;
Graves Disease*;
Humans;
Hyperthyroidism;
Recurrence;
Thyroid Gland
- From:Annals of Pediatric Endocrinology & Metabolism
2014;19(3):122-126
- CountryRepublic of Korea
- Language:English
-
Abstract:
Graves' disease (GD) accounts for 10%-15% of thyroid disorders in children and adolescents. The use of antithyroid drugs as the initial treatment option in GD is well accepted. An average two years remission is achieved in about 30% of children treated with antithyroid drugs. However, the optimal treatment duration and the predictive marker of remission after antithyroid drug therapy are still controversial. Additionally, 131I therapy and surgery are considered the option for treatment in children and adolescents with GD. We review the treatment options for pediatric GD and the possible determinants of remission and relapse on antithyroid drug treatment in children and adolescents.
